Assessment of more than 400,000 people over the age of 40 demonstrates that homozygosity for a CCR5 variant that prevents HIV-1 infection comes at the cost of increased rates of mortality.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Ryder, S. P. CRISPR J. 1, 355–357 (2018).
Gupta, R. K. et al. Nature 568, 244–248 (2019).
Wei, X. & Nielsen, R. Nat. Med. https://doi.org/10.1038/s41591-019-0459-6 (2019).
Keele, B. F. et al. Proc. Natl. Acad. Sci. USA 105, 7552–7557 (2008).
Samson, M. et al. Nature 382, 722–725 (1996).
Liu, R. et al. Cell 86, 367–377 (1996).
Stephens, J. C. et al. Am. J. Hum. Genet. 62, 1507–1515 (1998).
Hütter, G. et al. N. Engl. J. Med. 360, 692–698 (2009).
Hütter, G. N. Engl. J. Med. 371, 2437–2438 (2014).
Verheyen, J. et al. Clin. Infect. Dis. 68, 684–687 (2019).
Falcon, A. et al. J. Gen. Virol. 96, 2074–2078 (2015).
Bycroft, C. et al. Nature 562, 203–209 (2018).
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Luban, J. The hidden cost of genetic resistance to HIV-1. Nat Med 25, 878–879 (2019). https://doi.org/10.1038/s41591-019-0481-8